Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study is to show the new salt formulation of GSK372475 is equivalent to the old salt formulation of GSK372475.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GSK372475 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| GSK372475 plasma level at AUC0-72, AUC0-inf, CMax and TMax | at predose, 0.5,1-24, 36,48,60,72,96 and 1-4 weeks post dose. |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events | all visits | |
| vitals (all visits) + ECG | at screening,Day-1, predose, 1,6,24,48,72 and week 2 post dose. | |
| labs |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Toronto | Ontario | M1L 4S4 | Canada |
Not provided
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C577569 | GSK372475 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| at screening and 2 weeks post dose |